Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Stuart A. Tross, Chief People & Workplace Officer at MannKind Corp (NASDAQ:MNKD), sold 47,000 shares of common stock on September 16, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $5.34, with prices ranging from $5.33 to $5.39, for a total transaction value of $250,980.
Following the transaction, Tross directly owns 1,032,013 shares of MannKind Corp . The sale was executed under a pre-arranged Rule 10b5-1 trading plan established on June 17, 2025. With analyst targets ranging from $8 to $15 and the stock trading near its Fair Value according to InvestingPro, investors can access 11 additional exclusive ProTips and comprehensive analysis through the Pro Research Report, available for over 1,400 US stocks.
In other recent news, MannKind Corporation reported its second-quarter earnings, where profits aligned with analyst expectations at $0.05 per share, but revenue fell short of projections, coming in at $76.53 million compared to the expected $77.83 million. This revenue figure, however, still marked a 6% increase from the previous year’s $72.39 million for the same quarter. The company has also expanded its collaboration with United Therapeutics, receiving a $5 million upfront payment as part of an amended agreement to cover an additional development product. In a significant move, MannKind announced the acquisition of scPharmaceuticals for up to $360 million, which includes an upfront cash payment and contingent value rights. This acquisition adds FUROSCIX, a treatment for fluid overload, to MannKind’s portfolio. Analyst firm RBC Capital responded by raising its price target for MannKind to $8, maintaining an Outperform rating. Meanwhile, H.C. Wainwright increased its price target to $11, continuing a Buy rating, following positive clinical trial results for Tyvaso, a product from United Therapeutics. These developments highlight MannKind’s ongoing strategic initiatives and partnerships.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.